文献速递炎症性肠病

医师对炎症性肠病试验结果临床意义的看法:国际炎症性肠病研究组织(IOIBD)调查

Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-19

该调查面向IOIBD全体成员开展在线问卷,询问医师对炎症性肠病(IBD)试验结果临床相关性的判断。46名成员回复(52.3%)。多数人认为,在未使用过生物制剂的溃疡性结肠炎(UC)和克罗恩病(CD)患者中,临床缓解与内镜缓解相对安慰剂差15%具有临床相关性;在头对头试验中,组间差10%即被认为具有临床相关性。半数受访者认为非劣效试验中10%为合适界值,多数认为生物类似药与原研药在药代动力学、疗效、安全性和免疫原性上相差±5%为可接受。安全性方面,被认为具有临床相关性的差异范围为1%至5%,具体取决于不良事件类型。

要点

  • 未使用过生物制剂的UC和CD患者中,多数受访者认为临床缓解与内镜缓解相对安慰剂差15%具有临床相关性。
  • 头对头试验中多数受访者认为组间临床缓解与内镜缓解差10%具有临床相关性;半数认为非劣效试验10%为合适界值。
  • 生物类似药研究中多数受访者认为药代动力学、疗效、安全性和免疫原性相差±5%为可接受;安全性差异范围1%至5%视不良事件类型而定。

核心结论

  • 这是首个探讨医师如何理解IBD试验结果的调查,估算了可能直接影响临床实践的治疗组间差异幅度。

研究设计与样本

  • 对IOIBD全体成员开展在线问卷调查,询问其对IBD试验结果临床相关性的看法,共46名成员回复(52.3%)。

主要发现

  • 未使用过生物制剂的UC和CD患者中,多数受访者认为临床缓解与内镜缓解相对安慰剂差15%具有临床相关性。
  • 头对头试验中,多数受访者认为组间临床缓解与内镜缓解差10%具有临床相关性。
  • 半数受访者认为非劣效试验中10%为合适界值。
  • 生物类似药研究中,多数受访者认为药代动力学、疗效、安全性和免疫原性相差±5%为可接受。
  • 安全性方面,被认为具有临床相关性的两药差异范围为1%至5%,取决于不良事件类型。

关键数值与推荐

  • 未使用过生物制剂的UC和CD患者:多数受访者认为临床缓解与内镜缓解相对安慰剂差15%具有临床相关性。
  • 头对头试验:多数受访者认为组间临床缓解与内镜缓解差10%具有临床相关性。
  • 非劣效试验:半数受访者认为10%为合适界值。
  • 生物类似药研究:多数受访者认为药代动力学、疗效、安全性和免疫原性相差±5%为可接受。
  • 安全性:被认为具有临床相关性的两药差异范围为1%至5%,取决于不良事件类型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated. AIM: To better understand physicians' perspectives on the clinical meaningfulness of IBD trial results. METHODS: We conducted an online survey among all IOIBD (International Organization for the Study of Inflammatory Bowel Diseases) members, asking their opinion on the clinical relevance of the results of IBD trials. RESULTS: Forty-six IOIBD members responded to the survey (52.3%). In biologic-naïve ulcerative colitis (UC) and Crohn's disease (CD) patients, most of the participants considered a 15% difference with placebo for clinical remission and endoscopic remission to be clinically relevant. In head-to-head trials, most of participants considerer a 10% difference between groups for clinical remission and endoscopic remission to be clinically relevant. Half of respondents considered 10% to be an adequate margin in non-inferiority trials. In bioequivalence studies, most of the participants considered adequate a ± 5% difference between a biosimilar and the originator for pharmacokinetic parameters, efficacy, safety and immunogenicity. Regarding safety, the difference between two drugs considered clinically relevant varied from 1% to 5%, depending on the type of adverse event. CONCLUSIONS: This is the first survey exploring how physicians perceive IBD trial results, providing an estimation of the magnitude of the difference between treatment arms that may directly influence clinical practice.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Olivera P, Sandborn WJ, Panés J, et al. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018. PMID: 29349829. doi:10.1111/apt.14514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。